The prevalence of Type 2 diabetes mellitus (T2DM) continues to grow worldwide. Blood glucose control represents a central feature of risk factor management in patients with T2DM and several therapeutic options are now available to enforce blood glucose control. As a matter of fact, while before the year 2000 we only had 3 classes of drugs for diabetes (insulin, sulfonylureas, and metformin), 9 classes of drugs are now available, and several more are in a late development phase. This expands the range of clinical choice, but also forces the physician to face a more complicated array of options, where efficacy, safety, tolerability, and cost need to be carefully balanced.
展开▼